Drug development presentations will occur throughout Digital ILC 2021, ranging from late-breakers to general session presentations to dedicated sessions. Stephen and Jörn use the titles of presentation to discuss areas of drug development, paying particular attention to treating cirrhosis on one end and drugs that address defatting the liver through metabolic modes of action.
TOPICS: cirrhosis, EASL, efruxifermin, FGF-21, Madrigal, NAFLD, NASH, OCA, resmetirom, Digital ILC 2021, selonsertib, emricasan
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast